Renal Function

4

Review clinical trials related to Renal Function. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Multicenter, Prospective Blood Collection Study in a Kidney Transplant Population

The purpose of this research is to collect blood samples and data from kidney transplant patients. The samples and data will be used for research and development of non-invasive test to detect donor-derived cell-free DNA (dd-cfDNA) in kidney transplant patients to evaluate the status of the transplanted organ.

Participants needed: 400
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Devyser Inc.Updated: Dec 17, 2025Locations: 6
Eligibility criteria

Willing and able to provide written informed consent [+4]

Is pregnant [+5]

Status: Not yet recruiting

Association Between Qmax/eGFR Ratio and LUTS Severity in Men Over 40

This study will look at how well a measure called the Qmax/eGFR ratio is related to the severity of urination problems in men over the age of 40. Qmax is a test that shows how fast a person can urinate, and eGFR is a number that reflects kidney function. Men who have urinary symptoms will be asked to do a urine flow test, a blood test, and fill out a questionnaire about their symptoms and quality of life. We will study if there is a link between the Qmax/eGFR ratio and how severe their symptoms are. The results may help doctors better understand how kidney and urinary function are related in men with these problems.

Participants needed: 100
Trial details
Age: 40+Biological sex: MaleType: ObservationalSponsor: Marmara UniversityUpdated: Sep 5, 2025
Eligibility criteria

Male patients aged 40 years or older presenting with lower urinary tract symptom... [+4]

History of urological surgery (e.g., prostatectomy, bladder surgery) [+6]

Status: Recruiting

Evaluation of the Effect of Finerenone on Renal Function in Patients With Type 2 Diabetes and Chronic Kidney Disease

Research Objectives To evaluate the impact of finerenone on renal function, diabetic complications, and safety in patients with Type 2 diabetes and chronic kidney disease. Study Design Type: Prospective, single-arm, multicenter clinical trial. Sample Size: 300 patients. Intervention: Finerenone added to existing treatment regimen (10-20 mg once daily, dose adjusted based on eGFR), for 48 weeks. Data Collection Time Points: Baseline, 4 weeks, 12 weeks, 24 weeks, 36 weeks, and 48 weeks. Primary Endpoint: Change in urine albumin-to-creatinine ratio (UACR). Secondary Endpoints: Changes in eGFR, 24-hour urine protein, serum uric acid, retinopathy markers, pulse wave velocity (PWV), ankle-brachial index (ABI), etc. Safety Endpoints: Changes in serum potassium, sodium, and blood pressure.

Participants needed: 300
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Second Affiliated Hospital of Soochow UniversityUpdated: Apr 4, 2025Locations: 1Duration: 1 Year
Eligibility criteria

Diagnosed with Type 2 diabetes according to the 1999 WHO criteria [+4]

Chronic kidney disease diagnosed before Type 2 diabetes [+13]

Status: Recruiting

Urinary Creatinine Excretion Time in the Neonatal Period

Newborn's renal function is difficult to assess and its physiology during the first days of life is still incompletely known. Studies suggest that the newborn almost completely reabsorbs creatinine during the first 48 to 72 hours of life, while at the same time it continues to produce its own creatinine. Therefore, the initial stock of creatinine at birth still increases through this production and the non or weak clearance. A better knowledge of renal physiopathology in newborns would allow to improve the therapeutic management of the infants, particularly in case of potential nephrotoxicity. No study has attempted to assess the increase in urinary creatinine excretion in neonates from a given time. Objectives: To show when urinary creatinine excretion in newborns is efficient. Results: this study mightr show an inflection point in urinary creatinine excretion illustrating the postnatal age when renal function becomes efficient.

Participants needed: 40
Trial details
Age: Up to 3Biological sex: AllType: InterventionalSponsor: Central Hospital, Nancy, FranceUpdated: Feb 19, 2025Locations: 1
Eligibility criteria

All full-term newborns (37WA or more) [+3]

Newborns for whom no urine sample is interpretable [+2]